Physical Activity, Sedentary Behaviour and Cardiometabolic Health in Multiple Sclerosis

NCT ID: NCT05752630

Last Updated: 2023-03-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-30

Study Completion Date

2024-01-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the association between sedentary behaviour, physical activity, and the cardiometabolic health of Multiple Sclerosis via several cardiovascular, metabolic and anthropometric parameters.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Multiple sclerosis (MS) is an autoimmune, inflammatory and neurodegenerative disorder of the central nervous system, predominantly affecting young to middle-aged adults. The disease manifests in a broad spectrum of associated sensory, motor and psychological dysfunction, and there is a large variability in symptoms between (and within) persons with MS (PwMS). This can (partly) be explained by the co-existence of cardiometabolic (CM) diseases, such as hypertension, dyslipidaemia, insulin resistance or diabetes. More specifically, the presence of one or more of these CM diseases has been associated with a worsening of disability, independent of the timing of their development (at MS symptom onset, diagnosis, or later in the disease course). Therefore, the prevention and/or treatment of these CM comorbidities also warrant attention in MS rehabilitation.

In most studies PwMS and HC were matched on age, sex, height and weight. Importantly, differences in physical activity (PA) and sedentary behaviour (SB) were never taken into account, while this might be a relevant matching risk factor between groups. Moreover, Ranadive et al. found a significant worse vascular function in PwMS compared to HC, but differences were accounted for by low PA in PwMS. This might mean that PwMS can completely attenuate their increased CM risk by increasing their PA. However, this conclusion was only based on a statistical correction, there was a large difference in PA between groups and other confounding factors (such as PA intensity, smoking and nutrition intake) were not taken into account.

Therefore, the present study aims to investigate the relation between CM health and different intensities of PA and SB in PA-matched PwMS and HC. When CM health is comparable between PwMS and HC with similar PA levels, this shows the importance of including PA and SB measures and interventions as early as possible in MS treatment before automatically starting CM medication because PwMS are known to have multiple risk factors.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis, Relapsing-Remitting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy control

Healthy controls who engage in sedentary behaviour for more than 9 hours per day. Strata will be used to ensure equal distribution of active and inactive participants (\< and \> 150min/MVPA/week)

No interventions assigned to this group

Persons with MS

Persons suffering from MS who engage in sedentary behaviour for more than 9 hours per day. Strata will be used to ensure equal distribution of active and inactive participants (\< and \> 150min/MVPA/week)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Relapse-remitting MS
* 25-60 years old
* EDSS \< 5
* Sedentary behaviour (\>9hours daily)

Exclusion Criteria

* \<9h SB/day,
* experienced an acute exacerbation within 6 months before the start of the study
* an expanded disability status scale (EDSS) score \>5
* experimental drug use or medication changes in the last month
* medical conditions precluding PA participation
* alcohol abuse (\>20 units/week)
* reported dietary habits or weight loss (\>2kg) in the last month before the study
* intention to start a new specific diet or start to follow an exercise intervention
* reported participation in another biomedical trial which may have an effect on blood parameters 1 month before the start of the study
* blood donation in the past month
* diagnosis of cardiometabolic diseases such as diabetes mellitus or heart and vascular diseases.
Minimum Eligible Age

25 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hasselt University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bert Op't Eijnde

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bert Op 't Eijnde, prof.dr.

Role: STUDY_CHAIR

Hasselt University

Ine Nieste, drs.

Role: PRINCIPAL_INVESTIGATOR

Hasselt University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hasselt University

Diepenbeek, Limburg, Belgium

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bert Op 't Eijnde, prof. dr.

Role: CONTACT

+32 11 29 21 21

Ine Nieste, drs.

Role: CONTACT

+32496257499

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Bert Op 't Eijnde, prof.dr.

Role: primary

+3211292121

Ine Nieste, drs.

Role: backup

+32496257499

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CAMS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.